ContributorsPublishersAdvertisers

Single-Agent Adagrasib Achieves High Disease Control Rate in Pretreated PDAC and Other GI Cancers

targetedonc.com
 2022-01-21

Cover picture for the articleAccording to updated findings from a cohort of the KRYSTAL-1 trial adagrasib may be active in previously treated KRAS G12C¬–mutant gastrointestinal tumors. Promising clinical activity has been observed with adagrasib monotherapy in patients with previously treated pancreatic ductal adenocarcinoma (PDAC) and other non–colorectal gastrointestinal tumors that harbor KRAS G12C mutations, according...

www.targetedonc.com

Comments / 0

Comments / 0